PBM Rebate Settlements Belong in the Renewal File
The Federal Trade Commission's July 2026 Caremark settlement announcement is not just a pharmacy industry headline. It is another signal that rebate arrangements, list-price incentives, point-of-sale treatment, and PBM compensation are becoming boardroom-level issues for employer health plans.
The source idea is straightforward: federal scrutiny is moving toward how PBMs are paid, how rebates are handled, and whether drug pricing structures can create incentives that do not line up with patients or plan sponsors. The settlement follows the same broad theme as the Department of Labor's proposed PBM fee disclosure rule for self-insured group health plans: employers need more visibility into the money trail.
For CEOs, CFOs, and business owners, the lesson is not to memorize every legal detail. The lesson is to stop treating pharmacy as a black box inside the renewal.
Why This Matters To Self-Funding
A self-funded employer is not just buying an insurance product. The employer is paying claims, hiring vendors, and making fiduciary decisions around plan assets. That makes the PBM contract more than an attachment in the renewal packet.
If the PBM earns money from spread pricing, retained rebates, administrative fees, data fees, group purchasing organization arrangements, or list-price-linked compensation, the company needs to know how those dollars work. A lower headline discount may not be worse. A higher rebate may not be better. The right answer depends on total net cost, member impact, formulary incentives, and the employer's ability to audit the arrangement.
This is why pharmacy benefits should be reviewed like a business contract, not like a vendor promise.
The CFO Question Is Not "How Big Is The Rebate?"
Many renewal conversations still put too much weight on the size of the rebate guarantee. That can be misleading. A rebate is only one piece of the pricing machine, and a large rebate can still sit inside a structure that rewards higher list prices or hides value in other places.
The better CFO question is: after claims, discounts, dispensing fees, rebates, guarantees, admin fees, specialty pricing, and audit rights, what did the plan actually pay and who got paid along the way?
That question changes the meeting. It moves the conversation from "our PBM got us a good deal" to "show us the deal in dollars we can verify."
What Superior Insurance Advisors Would Put In The File
Superior Insurance Advisors and Paul.Health fit this kind of review because the work is practical. The goal is not to make the employer an expert in pharmacy law. The goal is to build a clean decision file before the renewal is signed.
For a PBM review, that file should answer these questions in plain English:
- Is the PBM paid on a pass-through, spread-pricing, rebate-retention, or hybrid basis?
- Are manufacturer rebates passed to the plan, used at the point of sale, retained, or shared?
- Does the contract disclose direct and indirect compensation?
- Can the employer audit claims, rebates, fees, specialty pricing, and guarantees?
- Are lower-list-price drugs disadvantaged by formulary economics?
- Does the employer receive claims-level reporting that can be used for decisions?
- Who is responsible for reviewing the PBM contract after the plan goes live?
Those questions are not academic. They determine whether the company has control or only a renewal story.
What Employers Should Not Assume
Do not assume the PBM's incentives match the employer's incentives just because the presentation says "savings." Do not assume rebates automatically help members at the pharmacy counter. Do not assume a carrier-owned or bundled arrangement gives the same visibility as an independent review. Do not assume the current contract will satisfy the next wave of disclosure expectations.
Most important, do not assume pharmacy can be separated from the broader self-funded strategy. Pharmacy cost, specialty drugs, chronic-condition management, member steerage, fiduciary process, and claims analytics all touch the same business problem: is the company buying care wisely, or just financing trend?
A Practical Renewal Checklist
Before renewing a self-funded plan with the same pharmacy arrangement, ask for:
- A plain-English map of how the PBM is paid
- A rebate and fee summary tied to actual plan experience
- Audit rights that are useful, not symbolic
- Specialty drug reporting that identifies top drivers and alternatives
- A formulary review that explains member cost impact, not only plan cost
- A fiduciary note showing who reviewed the arrangement and why it was accepted
The practical decision question is this: if a board member asked how the PBM made money from your plan last year, could you answer with documents instead of assumptions?
Book 15 minutes at www.Paul.Health if you want this reviewed against your current plan.